Brexpiprazole (Rexulti): A New Monotherapy for Schizophrenia and Adjunctive Therapy for Major Depressive Disorder
P&T (Pharmacy & Therapeutics)
Publication Date / Copyright Date
Mental health disorders affect approximately one in five adults in a given year. In the United States, approximately 1% of adults live with schizophrenia, and nearly 7% of adults have experienced at least one major depressive episode.1
The Diagnostic and Statistical Manual of Mental Disorders, fifth edition (DSM-5), defines schizophrenia as having two or more of the following symptoms for a substantial amount of time during a one-month period that leads to a significant decrease in level of functioning. The symptoms include grossly disorganized or catatonic behavior, negative symptoms (i.e., avolition or reduced emotional expression), and at least one of these symptoms: delusions, hallucinations, or disorganized speech.2
Medicine and Health Sciences | Pharmacy and Pharmaceutical Sciences
brexpiprazole (Rexulti), depression, schizophrenia, United States
Eaves, Shannon and Rey, Jose A., "Brexpiprazole (Rexulti): A New Monotherapy for Schizophrenia and Adjunctive Therapy for Major Depressive Disorder" (2016). Faculty Articles. 333.